Quince Therapeutics, Inc. – Special Call

Andrew Fein
H.C. Wainwright & Co, LLC, Research Division

Good morning, everyone. I’m Andrew Fein. I’m one of the biotechnology research analyst at H.C. Wainwright. It’s my pleasure this morning to host a HCW @ Home event, even though many of you probably are not at home, with Quince Therapeutics. Here from the company are its CEO and Chief Medical Officer, Dirk Thye; and Brendan Hannah, its Chief Operating Officer and Chief Business Officer.

So thank you both very much for being here this morning. We appreciate it. And maybe with that, the best place to kind of kick off is for people less familiar with the story, maybe you can give an overview and kind of speak to your focus on rare diseases, and then we’ll go from there.

Dirk Thye
CEO, Chief Medical Officer & Director

Sure. Thanks, Andrew. This is Dirk Thye here. I’m the CEO and the Chief Medical Officer, and the name of the company is Quince Therapeutics. We have a drug device combination, which is a platform technology. It’s a machine, a tabletop machine that takes blood a small volume of blood from a patient, 50 mills, so about the amount of double espresso. You take that amount of blood in a syringe, you hook it up to the machine and you process the blood to encapsulate a molecule inside of the patients on red blood cells. So it takes a small volume of autologous blood and you’re capable of putting a drug, a small molecule, a large molecule or even a protein inside of the patient’s red blood cells.